Keytruda shows OS benefit across broader range of lung cancer patients

Merck's drug improved overall survival in NSCLC patients with PD-L1 levels at or greater than 1%, according to an interim analysis.

By Jacob Bell • April 9, 2018

Incyte cancer study fails, setting back drug combo hopes

Dealing a major blow to Incyte, epacadostat failed to perform as expected in a closely watched study pairing the IDO inhibitor with Merck's Keytruda.

By Ned Pagliarulo • April 6, 2018

Explore the Trendline➔

Oncology's research boom

More than one quarter of the medcines cleared by the FDA's main review office since 2015 have been cancer drugs, a tally that reflects the advent of cancer immunotherapy as well as continued progress in matching treatment to genetics.

By BioPharma Dive staff

Conatus shares slide on emricasan study failure

The focus now turns to three trials Conatus is conducting with Novartis to test the experimental liver disease drug to treat NASH.

By Randi Hernandez • April 5, 2018

Boehringer joins checkpoint inhibitor race with OSE deal

In a heavily back-ended agreement, Boehringer is betting on a second wave of I/O drug development through the exploration of targets other than PD-1/L1.

By Ned Pagliarulo • April 5, 2018

Lilly's Cyramza succeeds in Phase 3 liver cancer study

Cyramza is one of a handful of new drugs Lilly is counting on to fuel growth.

By Suzanne Elvidge • April 5, 2018

Benefit of GenSight's gene therapy not so clear

Patients received GenSight’s candidate in one eye and a sham treatment in the other. Yet visual acuity in both eyes appeared to improve, puzzling investigators.

By Randi Hernandez • April 4, 2018

Allergan notches third trial success for depression drug

The Irish pharma aims to file cariprazine, currently marketed as Vraylar, for an expanded OK in bipolar I depression later this year.

By Suzanne Elvidge • April 4, 2018

Rigel's fostamatinib falls short in Phase 2

News of the setback weighed on shares of the biotech, which hopes to win U.S. approval for fostamatinib in another indication later this month.

By Ned Pagliarulo • April 3, 2018

MediciNova takes rollercoaster ride on multiple study readouts

Shares tumbled on news one of the company's drugs failed to promote methamphetamine abstinence, but later recovered on positive results in an unrelated liver disease trial.

By Randi Hernandez • April 2, 2018

Pfizer surprises ATTR rivals with tafamidis success

Shares in Alnylam and Ionis fell sharply after Pfizer said its experimental drug improved outcomes among certain ATTR patients in a late-stage study.

By Ned Pagliarulo • April 2, 2018

Redx study on hold before getting off the ground

A Phase 1/2a study has been halted for unspecified safety signals after dosing of the first patient.

By Suzanne Elvidge • April 2, 2018

Tesaro posts mixed Phase 2 data for Zejula combo

New trial results suggest Zejula and a PD-1 blocker may provide "meaningful clinical benefit," the biotech said. Some analysts didn't have such a rosy outlook, however.

By Randi Hernandez • March 28, 2018

Roche reports deaths of patients taking Hemlibra

The Swiss pharma said the recent patient deaths were judged unrelated to treatment, but the update stirred safety concerns for the newly approved drug.

By Ned Pagliarulo • March 28, 2018

Esperion bolsters cholesterol drug with new combo data

A mid-stage study showed adding Esperion's bempedoic acid to background treatment with PCSK9 inhibition delivered further LDL cholesterol lowering. 

By Suzanne Elvidge • March 28, 2018

Verona touts potential of mid-stage COPD drug

Jefferies called the drug a potential blockbuster and noted that, with strong Phase 2 data in hand, Verona would have a "compelling out-licensing opportunity in 2-3 years' time."

By Randi Hernandez • March 27, 2018

AnaptysBio's new allergy data has investors scratching their heads

A decision to exclude four patients with mild baseline symptoms from an interim analysis muddied otherwise positive results for its anti-inflammation drug.

By Jacob Bell • March 27, 2018

Protagonist halts colitis study after missed endpoint

Shares in the biotech plunged after the failure of its ulcerative colitis drug in Phase 2b study.

By Suzanne Elvidge • March 27, 2018

In push to use pot for pain, synthetics hold upper hand

The first plant-derived cannabinoid drug faces an FDA advisory panel meeting in April. If approved, it could swing the door to the cannabis market wide open.

By Randi Hernandez • March 26, 2018

Lilly's bet on pain stands out amid bare pharma pipeline

Even as the opioid epidemic has heightened the need for non-addictive painkillers, few pharma companies have made pain a therapeutic area of focus.

By Ned Pagliarulo • March 26, 2018

Biohaven falls on weak migraine data

The highly anticipated CGRP data disappointed investors, sending shares in the Connecticut biotech tumbling downward. 

By Lisa LaMotta • March 26, 2018

Ablynx's anti-inflammation drug fails in lupus

Vobarilizumab missed the primary endpoint of the mid-stage STEADY study, painting a gloomier outlook for Ablynx's opt-in deal with AbbVie.

By Jacob Bell • March 26, 2018

Roche's momentum grows as Tecentriq combo delivers survival benefit

Combining Tecentriq with Avastin plus chemo helped advanced lung cancer patients live longer, a result that could help Roche compete with class rivals.

By Ned Pagliarulo • March 26, 2018

Prescribed Reading: AbbVie disappoints; Regeneron deals in genes

Investors questioned AbbVie's strategy in oncology after a clinical miss. Elsewhere, Regeneron partnered with Alnylam to probe the potential of a genetic discovery.

By Lisa LaMotta • March 23, 2018

Novartis readies MS drug for speedy US filing

If approved, siponimod would become the first disease-modifiying treatment for secondary progressive MS, a later-onset form of the debilitating condition.

By Ned Pagliarulo • March 22, 2018

AbbVie oncology push in question after Rova-T disappoints

Results from the Phase 2 TRINITY study did not live up to AbbVie's — and investors' — expectations, casting a shadow on a major acquisition.

By Lisa LaMotta • March 22, 2018